Evaluation of real-world mepolizumab use in severe asthma across Europe: the SHARP experience with privacy-preserving federated analysis.
Johannes A KroesRafael Alfonso-CristanchoAruna T BansalEmmanuelle BerretKristina BieksieneArnaud BourdinLuisa BrussinoDiogo CanhotoCristina CardiniGulfem CelikZsuzsanna CsomaBarbro DahlénEbru DamadogluKatrien EgerLisa GauquelinBilun GemiciogluOzlem GokselSophie GraffEnrico HefflerHendrik B HofsteePeter J HowarthRupert W JakesFabienne JaunVirginija Kalinauskaite-ZukauskePeter KopačNamhee KwonClaudia Chaves LoureiroVictor Lozoya GarcíaMatthew MasoliMariana Paula RezeljLuis Pérez De LlanoSanja Popović-GrleDavid Ramos-BarbónAna Sà SousaKonstantinos SamitasFlorence SchleichConcetta SirenaSabina SkrgatEleftherios ZervasGeorge ZichnalisElisabeth H BelJacob K SontSimone HashimotoAnneke Ten BrinkePublished in: ERJ open research (2023)
By harmonising patient-level registry data and applying federated analysis, SHARP demonstrated the real-world effectiveness of mepolizumab on asthma exacerbations and maintenance OCS use in severe asthma patients across Europe, consistent with previous evidence. This paves the way for future pan-European real-world severe asthma studies using patient-level data in a privacy-proof manner.
Keyphrases
- big data
- chronic obstructive pulmonary disease
- end stage renal disease
- case report
- chronic kidney disease
- ejection fraction
- randomized controlled trial
- machine learning
- systematic review
- cystic fibrosis
- healthcare
- health information
- peritoneal dialysis
- prognostic factors
- social media
- patient reported outcomes
- case control